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ABSTRACT 
         Obesity is defined as a state of excess adipose tissue mass. In fact it is the 
total body fat content, which is important rather than total body weight. Diabetes 
mellitus is more importantly associated with obesity. Challenging the previous 
theory that obesity is protective against the development of osteoporosis, emerging 
studies had shown that obesity is detrimental rather than protective.  
Aims and objectives: 
          To Assess the Bone Mineral Density of obese and non-obese diabetics by  
the use of DEXA imaging. To study the impact of obesity on bone mineral 
metabolism. To correlate the vitamin D levels with the BMD of obese and non-
obese diabetics. 
Materials and method: 
         A total of 50 diabetic patients included in the study. The group was 
subdivided in to obese and non-obese with 25 in each group based on BMI. 
Patients who met the inclusion and exclusion criteria were inducted in to the study. 
Protocols were briefed. Investigations done apart from routine were vitamin D 
levels. DEXA imaging done was done for all the patients. 
Observations and results: 
        It was observed that out of 25 patients in obese group 16 were found to be 
osteopenic [64%] and only 3 had osteoporosis [8%].The prevalence of abnormal 
BMD in obese group was 80% [P <0.00] statistically significant. The percent fat 
mass [PFM] in obese group was 0.417 and in non-obese group was 0.286.When 
correlating with BMD the observation was statistically significant P<0.00. Both 
groups had insufficient vitamin D levels. The mean vitamin D levels in obese and 
non-obese were 23.1ng/dl and 27.6 ng/dl respectively. The observation of 
insufficient vitamin D levels was statistically significant P<0.00. 
Conclusion: 
       It was observed that obesity is an important risk factor for the development of 
osteopenia in diabetics. The most prevalent type of abnormal BMD in obese 
diabetics was osteopenia. Both groups had insufficient vitamin D levels.                         
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INTRODUCTION 
Obesity is defined as abundance of adipose tissue mass in the body. 
Contrary to popular belief, obesity is not synonymous with excess body 
weight. In fact it is proportional to total body’s fat content. Body mass 
index, the most commonly used measure of obesity is quantified by the 
formula weight in kilograms  to height in meter square [weight/height
2
], 
with a BMI of >30 is called as obesity, BMI between 25- 29.99 termed as 
overweight and a BMI ranging from 18.5 -24.99 is considered as normal. 
As obesity is considered as grade 1 failure of all organs, it is often linked 
to morbidity or mortality. 
Diabetes mellitus is the most prevalent endocrine disorder among 
the world’s population. India, now labeled as the diabetic capital of the 
world, has started feeling the brunt of the disease because of changing life 
style with low physical activity. Obesity and diabetes often go hand in 
hand, with obesity providing a substrate for insulin resistance. 
Metabolic bone disease associated with diabetes mellitus is a much 
underappreciated complication. Of these, Osteoporosis and osteopenia are 
important. Diabetes is an important cause of secondary osteoporosis.  
           Of the available techniques the DEXA [DUAL ENERGY X RAY 
ABSORPTIOMETRY] imaging provides an accurate measure of bone 
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mineral density. It provides a cumulative score namely T- score and Z- 
score, with a T –score of < 2.5 indicating osteoporosis and between -2.5 
and -1.0 indicating osteopenia. It also provides a quantitative measure of 
total body fat content in percentage. The pathogenesis of osteoporosis in 
diabetes mellitus is complex and controversial. Various studies have 
showed conflicting results portraying diabetes being protective as well as 
detrimental for the development of osteoporosis. The complex interplay 
between diabetes, obesity and osteoporosis is a matter of debate, with 
obesity and osteoporosis now being considered as interrelated disease 
because of common mesenchymal stem cell origin of osteoblasts and 
adipocytes. 
The mechanism by which obesity in diabetes predisposes 
toosteoporosis is not known. However the role of leptin anappetite 
hormone has been forayed in to the scenario. Leptin is produced from 
adipocytes found abundance in obese people, through its action on β2 
receptors via central sympathetic pathway, may lead to increased bone 
resorption. It is not known whether, the microvascular complications that 
occur in other vascular beds may possibly also occur in microvasculature 
of bone. 
With this study aimed at measurement of BMD in obese and non-
obese diabetics, the prevailing type of BMD in this subset of patients can 
be ascertained. The abnormal BMD that occurs in diabetes as a primary 
complication of the disease per se or as a consequence of obesity will be 
ascertained. 
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AIM OF THE STUDY 
 
 
1) To assess the bone mineral density of obese and non -obese 
 diabetic population by the use of DEXA imaging. 
2) To observe the impact of obesity on bone mineral density. 
3) To correlate the vitamin D levels and the BMD of obese and non -
 obese diabetics. 
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REVIEW OF LITERATURE 
Osteoporosis is a common mineral bone disease characterized by, 
abnormality in bone architectural pattern with resultant decrease in 
strength and enhanced susceptibility to fracture. It is classified in to 
primary and secondary with the former being the most commonest. 
Primary osteoporosis or idiopathic osteoporosis is seen 
predominantly in postmenopausal women, but can also occur in men who 
have underlying defects in bone formation
[23]
.  
Secondary causes of osteoporosis are related mainly with 
underlying endocrine disorders like diabetes, hyperthyroidism, Cushing’s 
syndrome, Hypogonadism and obesity 
[54]
.Other pro inflammatory 
conditions like Rheumatoid arthritis, Anorexia Nervosa, Chronic liver 
and renal disease may predispose to the development of osteoporosis.  
Osteoporosis is a quiescent disease till it presents with a fracture. 
Fracture of hip and vertebral bodies are more common in osteoporosis 
related fractures.  
Obesity is a state of excess adipose tissue mass. Were the 
distribution of fat in the body is more important than the type of fat. For 
example, the intra-abdominal and abdominal fat is metabolically more 
active when compared to subcutaneous fat elsewhere. Most important 
complications of obesity such as insulin resistance, diabetes, 
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dyslipidemia, osteoporosisare related to the lipolytically active fat that are 
present intraabdominally. 
Diabetes mellitus probably the most widely prevalent metabolic 
disorder among the world population .With the pandemic of disease at its 
peak, the knowledge   of existing complications in detail and the novel 
underappreciated complications like diabetic bone disease is essential for 
the holistic approach to these common disease. Thanks to the 
advancement in DEXA imaging diabetes related osteopenia/osteoporosis 
is being diagnosed at early stages of the disease. 
Prevalence of Obesity,Osteoporosis, Diabetes - World Scenario 
Incidence and prevalence of obesity and osteoporosis in general 
population shows a considerable variation among geographical regions. 
National Health and Nutrition Examination Surveys data from North 
America had showed the obesity prevalence of 32.2% in adult men and 
35.5% in adult women
[23]
. Data from Europe had showed that, the 
prevalence of obesity is maximum in United Kingdom with 12% and 
lowest being in Italy
[77]
. Among Asian countries with obesity Thailand 
leads the list with a prevalence rate of 6.2%
[76]
. 
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International comparison of prevalence of obesity and diabetes in 
adults 
It is estimated that 8 million women and 2 million men in the 
United States are osteoporotic and additional 18 million people are 
osteopenic
[23]
.The prevalence being more common in postmenopausal age 
group. Europe had reported maximum number of reported fractures 
related to osteoporosis in the world with 34.8%. The prevalence of 
osteoporosis in urbanized Asian countries had reached up to 
30%.However the exact prevalence of osteoporosis in obesity is yet to be 
ascertained. 
The prevalence of diabetes is 2.8% in 2000, but this figure will 
reach 4.4% in 2030 worldwide. The presence of generalized osteoporosis 
in diabetes is an underappreciated complication. Because of these along 
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with reporting bias the diabetic osteoporosis is less acknowledged and the 
data regarding its prevalence in diabetes is unknown. 
 
WORLD WIDE SCENARIO OF DIABETES
[72] 
Prevalence in Indian scenario: Increasing trend 
With India embracing both eastern and western lifestyle the 
prevalence of obesity has increased alarmingly, prevalence is between 10 
and 50% in various Indian cities. One study from urban Chennai has 
showed a prevalence rate of 22.8% in males and 31.8% in females
[74].
 
           To the same extent with the prevalence of obesity increasing, 
Osteoporosis had proportionally increased. One in eight males and one in 
three females suffer from osteoporosis, making India as one of the largest 
country with osteoporotic people. The affected people with osteoporosis 
are set to increase by 36 million by 2013
[78]
. A study by Britannia New 
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Zealand and arthritis foundation of India had revealed that people from 
Kolkotta and Chennai have a prevalence rate of 45%. 
           As of 2011 there are 61million diabetics in India. Recent Chennai 
Rural Urban Epidemiological Study[CURES] had showed a crude 
prevalence rate of 14.3% [age adjusted],with in a span of 14 years the 
prevalence had increased alarmingly by 73%
[75]
. But the data regarding 
prevalence of osteoporosis in diabetics is unknown because of the under 
appreciation of osteoporosis in diabetics. 
 
RISING TREND OF T2DM IN URBANIZED INDIAN CITIES AND THEIR 
PROJECTED OUTLOOK
[73]
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Demography: 
The usual age of onset of osteoporosis is beyond 50 years of age, 
mostly confined to postmenopausal women. Male to female ratio is 
1:2.66. With the increasing incidence of vitamin- D deficiency in Indian 
subcontinent the Indians are prone for the development of osteoporosis. 
Pathophysiology of osteoporosis: 
Osteoporosis is characterized by complex pathogenesis. During the 
period of growth till adolescence the bone formation exceeds bone 
resorption and after the age of 30 years the bone resorption tends to 
exceed formation
[1]
.The bone loss after menopause increases to 2-3 
percent per year as compared to premenopausal bone loss
[1]
. With 
cancellous bone being more metabolically active it bears the major brunt 
of the disease. The bone makeover has been linked with polymorphisms 
in the gene for vitamin D receptor(VDR)
[2]
. In addition polymorphisms in 
gene coding for estrogen receptor α (ERα) has been associated with some 
determinants of accelerated postmenopausal bone loss in women
[3]
. 
           The basic pathogenic mechanism in osteoporosis is excess skeletal 
tissue fragility which can result from: 
1)  Production of skeleton with decreased mass and endurance during 
 childhood and puberty 
[4]
. 
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2) Enhanced bone resorption leading to decremental bone mass and 
 distortion of architectural pattern of bone
[4]
. 
 
3) Deficient bone formation response[4]. 
 
 
COMPACT BONE SEEN IN HORIZONTAL AND VERTICAL SECTION 
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In order to realize, how an exuberant skeletal resorption and 
deficient bone formation result in osseous fragility, it is prudent to 
perceive the physiology of  remodeling process of bone, a phenomenal 
accomplishment by the bone cells of matured skeleton. 
 
MECHANISM OF BONE REMODELING 
Bone remodeling involves two imperious processes. First 
maintains skeletal strength by repairing micro damage to bone. Second 
constant supply of calcium to maintain blood calcium levels
[23]
.  
The remodeling process or bone multicellular units (BMUs) was 
first delineated by Frost and colleagues
[5]
 can occur either on the surface 
of cancellous bone as discontinuous Howship lacunae or secondly in the 
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cortical bone as an regular cylindrical Haversian systems. As depictedin 
the Figure remodeling starts with the stimulation of hematopoietic stem 
cells to differentiate in to osteoclasts. Two important cytokines needed 
for osteoclastogenesis are M-CSF(macrophage colony stimulating factor) 
and RANKL (Receptor Activator of Nuclear factor κβ). The receptor for 
RANKL is RANK and is expressed on the precursor cells of osteoclasts 
[15]
. Osteoprotegerin (OPG) is a decoy receptor for RANKL and opposes 
the osteoclastogenic action of RANKL
[15]
. 
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REGULATION OF OSTEOCLASTIC FUNCTION 
In this complicated remodeling process, the initial step will be the 
interaction between osteoblastic and osteoclastic cell lines. Macrophage-
Colony Stimulating Factor incorporates with its receptor, c-fms, to 
activate the proliferation as well as the differentiation of hematopoietic 
progenitors, which then express RANK as preosteoclasts. Osteoclast are 
stimulated by RANK/RANKL interaction, and this interaction is inhibited 
by osteoprotegerin(OPG). The COX2 activity is stimulated by bone 
resorbing factors which in turn produce prostaglandins and amplify the 
responses to RANKL and OPG. In pro inflammatory states, 
osteoclastogenesis may be increased by production of soluble or 
membrane bound M-CSF and RANKL along with PTH-related protein 
(PTHrP), cytokines, and prostaglandins
[4].
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These freshly differentiated osteoclasts needs an interplay with 
osteoblastic cell line. With osteoclasts holding center stage in the 
resorption phase, which is of shorter duration followed by reversal phase 
in which bony surface is encased by mononuclear cells. The osteoblastic 
replacement process takes a longer duration in which osteoblasts actives 
lay matrix over the scalloped surface produced by osteoclasts
[4]
.Whereas 
the resorption and reversal phases of remodeling requires a shorter 
duration, so any augmentation in the speed of remodeling process will 
lead to bone loss. With the number of under filled Howship lacunae and 
Haversian system increasing the strength of bone will be weakened 
proportionally 
[4]
. 
Enhanced resorption process leads to complete loss of trabecular 
structures, leaving no substrate for new bone formation. These are the 
various ways in which an increase in resorption function of osteoclasts 
can lead to brittleness of bone. Not always, high rates of resorption will 
lead to bone loss; one classical example being the pubertal growth spurt. 
Therefore deficient bone formation during the process of remodeling is an 
pivotal component in the pathophysiology of osteoporosis
[4]
. 
Pivotal role of estrogen:   
It’s a well-known fact that estrogen deficiency will leads to bone 
loss, as evidenced by increased prevalence of osteoporosis in 
postmenopausal age groups. Studies had proved that, bone remodeling 
process is accelerated at menopause as evidenced by the increased level 
of biomarkers for resorption and formation after menopause
[6]
. 
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Mechanism of estrogen deficiency leading to bone loss 
In contrary to Albright’s original hypothesis, the surge behind the 
bone loss in the light of estrogen deficiency is increased bone resorption 
and not impaired bone formation. Estrogen is both anti-catabolic and 
anabolic, suggested by the fact that the normally occurring increased 
bone formation response to mechanical loading, fails to occur in estrogen 
deficiency
[7]
. 
The amount of estrogen required to inhibit the resorption is less 
than one fourth that is needed for the growth of breast tissue and uterus
[8]
. 
Estrogen is required for epiphyseal closure in men and women. In 
addition, the lower estrogen levels are the most important cause of 
osteoporosis in older men than low androgen levels
[9]
.Estrogen has 
skeletal and extra skeletal activities, in skeletal action it has direct and in 
direct action. Direct action is mediated via estrogen receptors in 
osteoclasts and osteoblasts. The indirect effects are mediated via its 
Skeletal 
action 
Extra skeletal 
action 
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action on estrogen receptors on stromal cells. Estrogen deficiency will 
lead to increased expression of RANKL on bone marrow stromal cells, 
which is important for bone resorption
[16]
.Estrogen itself stimulates 
Osteoprotegerin(OPG) production in osteoblasts and antagonizes 
resorptive effects on bone
[17]
. The extraskeletal manifestations are 
increased renal calcium excretion and inhibition of calcium absorption 
from gut, these effects may lead to secondary hyperparathyroidism, in 
addition estrogen has suppressive action on parathyroid hormone 
levels
[18]
.  
Estrogen exerts its action via two receptors ERα and ERβ. The 
ERα is most important for its action [4]. Estrogen induces osteoclast 
apoptosis via TGF-β production [10]. It also reduces the amount of reactive 
oxygen species
[11]
.The osteo immunology behind estrogen deficiency is 
the increased production of IL-7, this in turn activates T cells. T cells in 
turn expresses TNF-α and INF γ and leads to over expression of  MHC 
(major histocompatibility complex) class 11molecules on the surface of 
bone marrow stromal cell which further leads to  more production of T 
cells and production of RANKL and TNF-α, both are pro 
osteoclastogenic. 
Role of vitamin D, calcium and parathyroid hormone: 
Calcium deficiency that results from either decreased intake or 
deficient absorption from intestine secondarily due to disease per se or 
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due to aging along with vitamin D deficiency leads to secondary 
hyperparathyroidism
[4]
.Vitamin D3 is needed not only for absorption of 
calcium from the small intestine but also for its negative influences on 
paratharmone
[12]
. Vitamin D deficiency and secondary 
hyperparathyroidism leads not only to increased bone loss and skeletal 
fragility, but also to increased frequency of falls which is more common 
in diabetics 
[13,14]
 probably due to neuromuscular impairment. Various 
trials had proved that vitamin D supplementation along with calcium in 
elderly people will results in increased bone mass along with reversibility 
of falls.  
 
Interrelation ship between parathyroid hormone,  
Vitamin D and calcium 
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Secondary hyperparathyroidism is commonly seen in patients with 
vitamin D insufficiency which is defined less than 30 ng/ml, hence forth 
the target vitamin D levels should be more than this level
[19]
. There is a 
seasonal decrease in vitamin D levels along with elevated levels of 
parathyroid hormone. There is also increased risk of cardiovascular 
mortality in people with secondary hyperparathyroidism, the mechanism 
behind this is unknown
[20]
. 
Receptor Activator of Nuclear Factor-κβ: 
 
 
X RAY CRYSTALLOGRAPHIC STRUCTURE OF NF-κβ 
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The Molecular mechanism behind the interaction between 
osteoblastic and osteoclastic lineages has been found recently
[21]
. The 
cytyokines responsible for this interaction belong to TNF (Tumor 
Necrosis Factor) family of receptors. Receptor activator of Nuclear 
Factor- Κβ is on hematopoietic cells, which is responsible for osteoclastic 
differentiation and function. RANKL/RANK interaction is necessary for 
bone resorption. Osteoblasts also secrete osteoprotegerin(OPG) which is 
a decoy receptor for RANKL/RANK interaction over expression of OPG 
knockout transgenic mice leads to development of Osteoporosis
[22]
. 
Recently a possible second system may be involved the interaction 
between osteoclastic and osteoblastic lineages, these are the Fc receptor 
common chain and membrane adapter DNAX-activating protein 12[4] 
 
Final common pathway that is altered in the pathogenesis of 
osteoporosis 
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Genetics in osteoporosis: 
The signal transduction pathways and transcription factors 
necessary for osteoblastic activity had shown several novel pathways to 
decipher and to understand the pathophysiology of osteoporosis
[4]
.Studies 
had suggested that  a genetic locus on chromosome 11 is associated with 
high bone mass. Recent Gene deletion studies have demonstrated that 
absence of runt-related transcription factor 2 (Runx2) or osterix, are 
critical for osteoblast differentiation
[24]
.The second fiddle played by the 
Wnt signaling pathway in controlling osteoblast activation is of great 
interest to researchers, and it was recently identified it plays an important 
role in determining bone mass and strength 
[4]
.  
The wnt signaling pathway is a network of messenger system that 
transfer the information from the cell surface to the nuclear DNA. 
LDL Receptor related protein 5 (LRP5) communicates with the 
frizzled receptor to transfer the message through Wnt ligands. Any 
mutation of LRP5 that leads to activation of wnt pathway at a constant 
rate will culminate in an increased bone mineral density 
[25]
.Deletion of 
LRP5 gene will result in osteoporosis along with abnormality in the eye 
movements. Loss of function mutations in the gene coding for LRP5 is 
seen in few of the patients with idiopathic juvenile osteoporosis. 
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Wnt pathway, BMP AND SCLEROSTIN 
Osteoblastic functional evolution depends on the functioning of 
wnt and BMP pathways. The signaling through wnt requires the interplay 
between LDL receptor protein 5 and the frizzled receptors (Frz) and in 
turn this interaction can be inhibited by Dickkopf (DKK; an inhibitor of 
LRP5) and secreted frizzled related protein (SFRP). Antagonists such as 
sclerostin blocks both the BMP and Wnt signaling. The β-catenin can 
form an alliance with BMP2 to intensify the osteoblastic function. 
The Wnt signaling pathway is crucial to responsiveness of the 
effects on mechanical loading on bone 
[27]
.Wnt signaling can affect the 
peak bone mass 
[28]
.  
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Glucocorticoids mediates its effect on skeletal structure through 
Wnt signaling 
[29]
.There is an association between bone mineral density 
with the occurrence of osteoporosis related fractures and polymorphism 
in the genes encoding IGF1 and TGF-β [30],but a study from Icelandic and 
Danish cohorts, shows that polymorphisms involvingBMP2 (bone 
morphogenic protein)gene are associated with low BMD and fracture risk 
[31]
.Local production of IGF-1may be the cause ascribed to 
glucocorticoid-induced osteoporosis as also to the growth inhibition in 
childhood
[29]
. 
Role of inflammatory mediators: 
The chemokines such as interleukin -1(IL-1) and prostaglandin E2 
(PGE2) can affect bone remodeling process
[32]
. Prostaglandins have both 
agonistic and antagonistic effects on bone. However, the most important 
action of PGE2- the most abundant prostaglandin synthesized in skeletal 
tissue, is to enhance bone resorption and subsequently bone formation 
[33]
. 
The fact that these chemokines may play an important role in the 
evolution of osteoporosisis proved by experimental models of skeletal 
loss after gonadectomy
[34]
. The genetic polymorphisms of interleukins 1, 
6 and tumor necrosis factor α and their receptors can affect the osseous 
mass in humans 
[4]
. 
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                  PGE2 is synthesized in bone cells mainly by the effect of 
inducible cyclooxygenase 2 (COX2).Cyclooxygenase is stimulated by the 
factors that may also induce resorption of bone and may augments the 
riposte
[35]
.Treatment with Cyclooxygenase blockers decreases the 
response to mechanical effects of weight bearing and fluid shear stress. 
Prostaglandins have pivotal role to play in response to weight loading, 
and this effect is augmented by estrogen 
[36]
.  
In addition to endothelial cells, NO synthesized in bone cells is an 
important cofactor for the growth response of bone to weight 
bearing
[4]
.NO inhibits bone resorption, possibly by increasing OPG 
production there by having opposing action to PGE2
[37]
. This may be the 
possible reason for the enhanced Bone Mineral Density that is seen in 
patients on nitrates and various  
NO pathway activators 
[4]
.Leukotrines the products of 
lipooxygenase cascade can also influence the bone remodeling by 
enhancing bone resorption and blocking the bone formation process
[38].
 
Matrix abnormalities- A Novel hypothesis: 
Recent investigations had proved that polymorphisms in gene 
coding for α1 chain of  type 1 collagen along with hyperhomocystenemia 
will lead to fracture risk that is independent of  BMD, probably due to 
difference in collagen cross linking and helix formation
[39]
. 
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Leptin and other neural pathways: 
Leptin is the appetite hormone. Mice knocked out with leptin gene 
had higher BMD than Mice with leptin gene, suggesting the role of 
obesity as important risk factor for the development of osteoporosis. As 
adipocytes are the major source of leptin, it mediates it action via central 
adrenergic action
 [40]
. The role of  leptin is discussed in detail in the 
section of obesity and osteoporosis. 
OBESITY A NEW RISK FACTOR FOR OSTEOPOROSIS? 
In the era of evidence based medicine, what holds true today may 
not hold for tomorrow. This is very much applicable for obesity. The old 
concept that obesity is a protective factor for the development of 
osteoporosis is no longer holds true. Recent studies had clearly proved 
that obesity is not protective and in fact it is detrimental for the 
development of osteoporosis
[41,85-87]
. 
The primary action of skeletal framework is to offer a tough core to 
back up, preserve, and promote the activities of soft tissues. Ribs, skull 
and pelvis safe guard their contents. The ribs will be essential for thoracic 
movements, like wise femur and tibia are important for ambulation. 
Therefore it is credible from maturation point of view, that the skeletal 
framework’s endurance would be closely related to soft tissue mass. If all 
humans had the similar sized skeleton irrespective of their body weight, 
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few maybe at disadvantage of having bones that were inefficient to 
perform the task, and few might be having a heavier frame of skeleton 
than it need to be. 
Body weight is a composition of lean mass and fat mass
[41]
. It 
should be emphasized that, the simple correlation between lean body 
mass and mineral content of bone tends to overestimate the relationship 
BMD and muscle mass
[42]
. Muscle mass and bone mineral content are 
conspicuously depends on height, but the bone density is an independent 
variable that does not depend on height. Simply, longer legs in taller 
individuals have larger muscle mass to cover them. Hence larger mass 
imparts a greater mechanical loading on the bone. Emerging studies are 
now concentrating on new variable called percentage fat mass. Bakker et 
al
[63]
found that fat free mass had correlated positively with lumbar bone 
mineral content over 10 year follow up period in young subjects. Because 
fat free mass [FFM] can be accounted as a proxy for skeletal muscle 
mass. Observation from bakker et al indicate that the importance of 
muscle contractions to increase bone strength in the study population
[63].
 
Review of existing concepts about obesity and bone mass: 
It has been proved from the vast available epidemiological data 
that the excess bodyweight will result in a high bone mass, so reduction 
in the weight may lead to bone loss 
[44,45,46]
. The physiology behind this 
interrelationship is not clear, although several plausible reasons have been 
advocated. It is an accepted hypothesis that heavier the body mass bigger 
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will be the impact of shear stress on bone and that bone mass increases 
proportionately to accommodate the load. In postmenopausal women the 
major source of estrogen is adipocytes. Estrogen by blocking the activity 
of osteoclasts inhibits the resorption process. The argument being any 
increased adiposity will increase the body mass index in postmenopausal 
women. This effect may translate into decreased osteoclast mediated 
resorption with resultant increase in bone mineral density
[47]
. 
Obesity leads to insulin resistance and increased insulin levels 
causes an increased synthesis of androgens as well as estrogen and 
decreased production of sex hormone binding globulins by liver which in 
turn causes increased levels of free sex steroids and stimulation of 
osteoblastic activity  by sex steroids. Recent developments in science had 
questioned this concept. 
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The relationship is far more complex as thought between these 
variables. The discovery of appetite hormone leptin and its role in energy 
metabolism had thrown light on its influences bone metabolism
[51]
. Ducy 
et al had reported that leptin receptor and leptin deficient mice had 
showed increased bone formation. Leptin-deficient and wild-type mice 
had showed bone loss when leptin was injected to cerebral ventricles
[51]
.  
LEPTIN- ROLE IN OSTEOPOROSIS: 
Leptin meaning thin is a 16-kDa protein , called as satiety hormone 
plays a very crucial role in regulating energy intake and expenditure 
including gappetite/hunger and metabolism. It is an adipose tissue derived 
hormone. The leptin gene is located on chromosome 7 in humans
[52]
. 
 
CRYSTALLOGRAPHIC STRUCTURE OF LEPTIN 
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Human leptin has 167 amino acids. It is synthesized primarily 
from white adipocytes, and the amount of leptin circulating in plasma is 
directly proportional to the total body fat content. The other sources of 
leptin are from brown adipose tissue, skeletal muscle, fundic glands, 
syncytiotrophoblasts of placenta, ovaries, mammary cells, pituitary, liver 
and bone marrow
[53]
. 
The fact obesity and osteoporosis are interrelated disease can be 
explained by the fact that both adipocyte and osteoblast arises from 
common mesenchymal cells
[55]
. Mesenchymal cell upon its differentiation 
is committed for pre-osteoblasts and pre-adipocyte. But upon stimulation 
by the cytokine called Peroxisome Proliferator Activated 
Receptor(PPAR-γ) the mesenchymal stem cell is more committed 
towards the differentiation in to adipocyte. Hence further, adipocyte 
expresses its hormones like estrogen, leptin, adiponectin and resistin
[55]
.  
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Physiology behind the adipocyte differentiation 
Adiposity signal: 
Till date, only insulin and leptin are known to act 
as adiposity signals. In general, 
 Circulating leptin levels parallels body fat content. 
 Proportional to its plasma concentration it enters central  
  nervous system. 
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 Leptin receptors are found in central nervous system neurons 
  and  appear to play a major role in maintains the energy 
  intake and  output. 
 Controls energy expenditure and food intake through its  
  action on medial basal hypothalamus. 
Leptin mediates its effect on bone through central sympathetic 
action
[54]
. The central sympathetic action involves both catabolic and 
anabolic pathways.  Physiologically the catabolic pathway seems to have 
a major effect on the bone metabolism
[54]
. 
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Leptin via its action through pro-opio melanocortin leads to 
stimulation of α-melanocyte stimulating hormone(α- MSH). α- MSH 
exerts its action via two melanocortin receptors MC3R and MC4R. 
Leptin by inhibiting agouti related peptide which is are endogenous 
antagonist to melanocortin receptor leads to bone loss
[55]
. 
Sympathetic effects of leptin: 
To emphasize the Original study from Ducy et al[51] which 
showed bone loss in mice infused continuously with leptin leads to bone 
loss. Though leptin has both positive and negative effects on the bone, it’s 
the positive effect that is more important in vivo
[55]
.   
 
 
 
 
 
 
 
EFFECTS OF LEPTIN ON SYMPATHETIC 
PATHWAY IN CNS 
LEPTIN
 
 
 
NOR ADRENALINE 
NOR ADRENALINE 
 
B2 RECEPTORS 
 
INCREASED EXPRESSION OF RANKL 
 
INCREASED OSTEOCLAST MEDIATED 
RESORPTION. 
 
NOR ADRENALINE 
 
B2 RECEPTORS 
 
ALTERATION OF C-myc AND 
CYCLIN-D EXPRESSION 
 
INHIBITS  OSTEOBLAST 
FORMATION. 
 
 
 
38 
 
Leptin via its action on β2 receptors which is mediated by 
noradrenaline increases the expression of receptor activator of Nuclear 
Factor κβ [NF-κβ] mediated via phosphorylation of protein kinase A 
pathway. Therefore it increases the osteoclast mediated bone resorption. 
In addition via the same pathway it causes alteration in c-myc expression 
leading to inhibition of osteoblast mediated bone formation
[55]
.Leptin 
receptor–deficient db/db mice and Leptin-deficient ob/ob mice are 
extremely obese
[56]
. Some studies had proved direct effect of leptin on 
cortical bone formation but not on cancellous bone. 
Role of other adipocyte derived hormones: 
In addition to leptin, the adipocyte derived hormones are important 
in influencing bone mineral metabolism. 
Adiponectin : 
It is an adipocyte derived hormone that has anti-inflammatory and 
anti atherogenic effect 
[57]
, apart from energy metabolism and bone 
homoestasis. In contrast to leptin levels which are elevated in obesity, 
adiponectin levels are suppressed in obesity and also in diabetics
[55]
.  Its 
receptors are seen in  
Primary human osteoblasts
[58]
.Pioneering studies from LenchikL et 
al had proved an inverse relationship exists between bone mineral density 
and serum adiponectin levels
[58]
. Subsequent studies had shown 
 
 
39 
 
conflicting results, clearly indicating further studies are needed to 
undermine the role of adiponectin and its influence on bone metabolism. 
Resistin:  
Resistin, an adipocyte-secreted factor discovered recently. This 
Hormone was discovered during a screening process in patients with oral 
hypoglycemic agents (insulin sensitizing drugs) for an unknown 
substance which was down regulated in diabetics. It has been claimed to 
be associated with diabetes and obesity 
[59]
and the serum resistin levels 
were elevated in proportion to the degree of obesity
[59]
.Thommesen et al 
[60]
 had showed resistin may mediate an important effect on remodeling 
the bone. Resistin is expressed in osteoblasts, osteoclasts and bone 
marrow cells and they help in cytokine expression, osteoblast 
proliferation, and osteoclast differentiation
[60]
.Oh et al studied the 
relationship between serum resistin levels and bone mineral density. They 
found   converse relationship between serum resistin levels and BMD of 
lumbar spine in adult men, but they found out that variance was small
[61]
. 
Brief view on other hormones that influences obesity and BMD: 
Insulin: 
Obesity is synonymous with Insulin resistance and numerous 
studies had underscored the fact that insulin is an important orchestrator 
in bone metabolism. The Fasting levels of insulin were correlated 
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affirmatively with BMD of middle-aged women 
[55]
. Similar correlation 
was shown in both sexes in other studies. Tuominen et al 
[62]
showed that 
individuals diabetes have reduced BMD compared with normal 
individuals. Contrasting studies have revealed insulin may aid the 
protective effect of obesity. Elevated insulin levels in obesity is because 
of resistance and related with overproduction of estrogen, androgen and 
diminished synthesis of sex hormone-binding globulin by the liver 
[4].
The 
unbound sex hormones leads to suppressed osteoclastic and enhanced 
osteoblastic activity culminating in high bone mass
[4]
.But these finding is 
not reproducible in recent studies. Like the complicated relationship 
between fat and bone, so is the relationship between insulin and bone that 
is too complex to understand. The fact that obesity is sometimes called as 
diabesity is because, only 10% of obese people suffer diabetes on the 
contrary most of the diabetics are obese. The paucity of insight in the 
continuum of obesity may be the fact behind the discrepancies in the 
literature with regards to the fat and bone relationship 
[55]
. 
Amylin: 
Amylin is co-secreted along with insulin. It is a 37-amino acid 
peptide, a member of the calcitonin family of hormones.The obese 
individuals have higher basal amylin levels when compared with controls 
[55]
.By its central and peripheral mechanisms amylin infusion seems to 
decrease food intake and has capacity in attenuating body fat and weight. 
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The increased amylin levels in obesity leads to down regulation of amylin 
receptors and dampens the effect of  amylin secretion on gastric emptying 
and satiety. Amylin has been shown to suppress osteoclast development 
there by inhibiting bone resorption. 
The net effect is high amylin levels in obesity leads to high bone 
mass
[55]
. 
Preptin: 
Preptin is a 34-amino-acid peptide hormone secreted from β cells 
of Pancreas, Corresponding to Asp- Leu of the proinsulin-like growth 
factor II(proIGF-II) E-peptide. Circulating levels of preptin are elevated 
in obesity
[55]
.It is co-secreted with amylin and insulin from the pancreatic 
βcells. The Cornish et al[63]focused on preptin’s effects on bone and they 
proved that preptin is agonistic to bone growth in vitro as well as in vivo. 
But the fact is, it does not influence the osteoclast activity. 
Diabetes and osteoporosis: 
Diabetes mellitus is a pandemic endocrine disorder with substantial 
morbidity and mortality. The skeletal manifestations of diabetes mellitus 
are 
1) Diabetic foot syndrome. 
2) Charcot’s arthropathy and the much under appreciated  
3) Osteopenia and osteoporosis. 
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Osteoporosis is the most outstanding metabolic bone disease in 
diabetics 
[64]. 
Metabolic abnormalities of bone in patients with diabetes 
may be the direct consequence of insulin deficiency or insulin resistance 
and hyperglycemia on the bone and its metabolic milieu. The effects may 
also be due to advanced glycation end products (AGEs), adipokines, 
abnormal cytokine production and their deleterious effects on bone cells 
and neuromuscular/skeletal interactions
[64]
. 
Iowa Women’s Health Study had showed that women with type 1 
diabetes mellitus were at risk of hip fractures than without T1DM 
[65]
.In 
the same way women with T2DM are at more risk of developing fractures 
than without it. Longer duration T2DM predisposes to frequent falls 
probably because of associated peripheral neuropathy, thus increasing the 
probability of having fractures despite having better BMD
[64]
.It is prudent 
to provide appropriate clinical intervention to skeletal disease in order to 
achieve an optimal bone health in these patients. 
Possible mechanisms and risk factors for osteoporosis in T1DM: 
The presence of micro and macrovascular complications for a 
prolonged period with poor glycemic control rather than duration of 
disease per se predisposes to lower BMD in T1DM.The complications 
include retinopathy, nephropathy, peripheral neuropathy, and peripheral 
vascular disease. Both retinopathy and peripheral neuropathy leads to 
hampering of physical activity and neuromuscular/ skeletal interactions, 
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and enhanced  susceptibility to fall causing lowering of BMD
[65]
.One 
study had proved that patients with retinopathy has 72% chance of having  
lower BMD. Both peripheral neuropathy and nephropathy has been 
linked to poor bone mineral density
[65]
.  
Possible mechanisms behind these changes in T1DM are 
insulinopenia and the anabolic effects of insulin on bone is lost, also the 
co-existing amylin deficiency also contributes to lower BMD because of 
increased osteoclast mediated bone resorption
[65]
. 
Possible mechanisms and risk factors for osteoporosis in T2DM: 
The discrepancy between the onset of the disease and the diagnosis 
of T2DM is a very important factor in determining its major 
complications such as metabolic bone disease. There is usually a time lag 
of at least 5-10 years between the onset and diagnosis of diabetes. The 
Rotterdam study, so far the largest study on BMD in diabetics had 
showed treated diabetic patients are at increased risk of fractures in spite 
of having better BMD
[65]
. 
In contrary to T1DM with absolute insulin and amylin deficiency, 
T2DM is associated with resistance to insulin action peripherally there 
will be an impaired secretion of insulin following a metabolic challenge 
with glucose. Hyperglycemia is a potential detrimental factor affecting 
bone homeostasis. 
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Effects of diabetes on metabolic milieu of bone. 
Uncontrolled hyperglycemia is the major contributing factor for all 
the pathophysiological consequences in patients with diabetes. The 
intricate relationships between hyperglycemia and BMD have not been 
studied in detail. The osteoclast derives its nutrition mainly from glucose 
and it has a robust machinery to dose-dependently modify its function in 
vitro. Hyperglycemia may impair bone quality by non enzymatic 
glycosylation of type I collagen and various bone proteins. 
Other possible deleterious effects on bone homeostasis by 
uncontrolled hyperglycemia includes increased urinary calcium excretion 
which is secondarily due to elevated renal threshold to glucose excretion 
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and possible interplay between elevated blood glucose concentrations and 
PTH/vitamin D system. A study in small healthy cohorts had showed 
hypercalciuria and hypocalcemia which was associated with diminished 
levels of parathyroid hormone after challenge with oral glucose load
[65]
. A 
study in hospitalized patients with T2DM proved that return of the 
euglycemic status resulted in normalization of urinary calcium and 
phosphate excretion, serum vitamin D levels and the elevated serum 
phosphate levels, but without undue responses in PTH levels or serum 
calcium. 
A prevalence study from New Zealanders revealed lower serum25- 
Hydroxyvitamin D3 levels in subjects with newly detectedT2DM and in 
patients with impaired glucose tolerance. In a prospective study from 
Dutch people 39% of people with T2DM,associated with vitamin D 
deficiency. However with regards to controversy surrounding obesity in 
diabetes, possibly the adverse effects of hyperglycemia on the bone 
homeostasis are heavily counterbalanced by the beneficial effects of 
obesity on bone mineral density, a theory now strongly being challenged. 
The role of adipokines on human disease had been studied in great 
detail.Leptin the best-studied adipokine so far with regard to its effects on 
bone was briefly discussed earlier. Recently, adiponectin and resistin 
have been shown to execute its protective effects of obesity on the 
skeleton .Two principal pathways that were proposed to influence the 
skeletal effects of leptin are central and peripheral. Both these paths have 
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opposite effects. The predominant central effect on the skeleton isby 
restraining osteoblast proliferation there by leading to suppression of 
bone formation. The central effects are mediated through sympathetic 
pathway. The central pathway is the major way by which it mediates its 
action. The receptors for adiponectin are expressed on both osteoblastic 
and osteoclasticcell lineages and osteon synthesis in cultured 
osteoprogenitor cells is suppressed by adiponectin. This suppression was 
blunted in the presence of insulin.  
Resistin too is produced by both osteoblastic and osteoclastic cell 
lineages. Resistin stimulates the osteoclast development and has no effect 
on osteoblastic differentiation. Together the adipokines have both 
positive as well as negative effects on bone homeostasis that do not fully 
account for an better bone mineral density values in obese people. 
Adiponectin levels are depressed in both obese and diabetic people and it 
antagonizes the inflammatory mediators there by offering protection to 
endothelial and vascular smooth muscle cells, and has beneficial effects 
on ventricular remodeling. These adipokines in over all have a net 
beneficial effect on osseous microenvironment in patients with T2DM, 
However their unwarranted effects on the cardiovascular system make the 
patients with T2DM susceptible to falls, which makes them fracture 
prone that has been related to osteoporosis despite higher BMD. 
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Clinical recommendations based on evidence based medicine: 
Most of the current osteoporosis therapeutic intervention trials 
Involve the diabetic population. There no consensus based guidelines 
currently.  Exist to direct the interventional models in the management of 
diabetic osteoporosis. Any patient with T2DM represents a prognostic 
and diagnostic perplexity because the importance of measuring BMD to 
assess the osteoporotic fracture risk is constrained by two main factors:  
1) Defective quality of bone. 
2) Increased susceptibility to falls.  
Maintenance of euglycemic status is essential to curtail the degree 
of non-enzymatic glycosylation of type 1collagen in the bone. Vascular 
complications are delayed by maintaining adequate glycemic control. It is 
essential to have a check on the risk factors for the falls and consideration 
should be given to the neurological and cardiovascular status in addition 
to assessing the balance. 
A recent meta-analysis has advocated proper implementation of 
systematic exercise program to improvise the muscle strength, improve 
the balance, and proprioception, visual health with attention to cataracts, 
use of hip braces to decrease the risk of falls and fractures
[67]
. Calcitriol 
and oral calcium supplementation had shown encouraging out comes in a 
small cohort of nondiabetic women with attendant reduction in fracture 
rate by almost 50%. It still remains elusive whether this can also be 
extrapolated to diabetic people. 
 
 
48 
 
 
 
 
 
 
 
         NORMAL BONE IN HRCT             OSTEOPOROTIC BONE IN HRCT 
Methods to assess Bone Mineral Density: 
Currently there are various methods available to qualitatively 
assess the mineral contents of the bone. All of them are noninvasive with 
low radiation hazard. 
These tests include: 
1) Dual-energy X-ray absorptiometry (DXA or DEXA) 
2) Quantitative computed tomography (QCT) 
3) Qualitative ultrasound (QUS) 
4) Single photon absorptiometry (SPA) 
5) Dual photon absorptiometry (DPA) 
6) Digital X-ray radiogrammetry (DXR) 
7) Single energy X-ray absorptiometry (SEXA) 
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Though ultrasound had proved cost effective, DEXA still remains 
the most commonly used. It is a sensitive assay to assess the bone mineral 
density. 
DUAL ENERGY X RAY ABSORPTIOMETRY: 
Dual-energy X-ray absorptiometry is the best technique that is 
currently available to measure bone density (BMD). The physics behind 
the genesis of dual energy X ray is that, X rays are generated  in Coolidge 
tube by tiny negatively charged particles called electrons which exists 
from a wire filament when heated. These electrons are accelerated by 
high voltage towards metal target made of tungsten. In the target some of 
the electron kinetic energy is converted into X- ray energy. When X ray 
particles are passed through the human body there is attenuation in the 
intensity of the beam. Now to measure the BMD, X ray beam is passed 
through the bone and the attenuation is measured and expressed in 
gram/cm2 which accounts for mineral density of bone. Likewise in dual 
energy X ray absorptiometry, attenuation is measured between high and 
low energies. Previously used in this technology are radioactive 
gadolinium 153 because of potential hazards associated with its use the 
photons are replaced by X ray tube 
[70]
. Typically this technique involves 
scintillation detector mounted on C arm. The purpose of this 
arrangement is to expose the patient in a pencil beam of x rays in a 
rectilinear fashion. 
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DEXA SCANNER 
Measurements of the variables from the DEXA scan: 
The values are scored by T- score and Z- score. Each of this score   
ranges from negativity to positivity. A Negative score indicates decreased 
BMD and a Positive score indicating higher. In addition it measures fat 
content in grams, lean mass, regional fat content and bone mineral 
content. 
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PARTS OF DEXA SCANNER 
Importance of T- score: 
For the measure of osteoporosis the relevant variable is T score. A 
T score may show how much a bone mass may deviate from the average 
bone mass of a healthy adult. It refers to the bone mineral density of that 
particular site compared with young normal reference mean population. 
In simplistic terms it is the comparison of bone mineral density of 
patients with that of a normal 30 year old of same sex and ethnicity. This 
value is compared with that of postmenopausal women and men over 
fifty years of age to evaluate the risk of osteoporosis
[71]
. One standard 
deviation refers to 10-20% difference in bone mass. For example if the 
patient’s bone is less dense its SD -2 or -3 indicating the patient’s bone is 
20 to 30% less dense than average 30 year old.  
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WHO CRITERIA FOR OSTEOPOROSIS: 
T- SCORE DIAGNOSIS 
> - 1.O ADEQUATE BMD 
-1.O TO -2.5 OSTEOPENIA 
< - 2.5 OSTEOPOROSIS 
< - 2.5 with fractures SEVERE OSTEOPOROSIS 
 
WHO- WORLD HEALTH ORGANIZATION 
Importance of Z score: 
A Z-score compares the patient’s bone density to the average for  
same age and gender. For example a 60 year female patients BMD is 
compared with that of average BMD of 60 year old females. In simplistic 
terms it is comparison of age matched normal. It refers to the number of 
times in standard deviation in which patients BMD differs from that of 
their age, sex and ethnicity. For evaluation of osteoporosis T score is 
considered more significant than Z score. 
Z score Diagnosis 
> - 1.5 ADEQUATE BMD 
-1.5 TO -2.5 OSTEOPENIA 
< - 2.5 OSTEOPOROSIS 
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Radiation dose in DEXA imaging: 
Albabese et al had compared various modalities of radiological 
investigations and the radiation dose associated with it. It has been found 
that the average DEXA scanner exposes the patient to radiation dose of 
0.3 micro Sievert units this is hardly any radiation dosage when compared 
with chest X ray, which carries a radiation dosage of 50 micro Sievert 
units. Similarly Njeh et al had proved the radiation dose was negligible 
when compared with environmental exposure. 
 
Comparison of available radiological investigation’s in respect to 
their radiation dosage. NOTE; New generation pencil beam DEXA has 
an exposure rate of 0.3- 0.4 micro Sieverts. 
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Relationship between obesity, osteoporosis and diabetes mellitus-
Unifying the topics: 
Obesity and diabetes mellitus are a part of metabolic syndrome. It 
has been observed from various studies that majority of patients with 
diabetes mellitus suffer from obesity on the contrary, only less than 10% 
of patients with obesity suffer from diabetes mellitus
[64]
 .To favor this fact 
majority of osteoporotic treatment studies involves obese diabetics 
[64,65]
. 
Emerging observations from western literature have implicating 
that diabetes mellitus is no more protective against the development of 
osteoporosis 
[64]
.To some extent osteoporosis is even called as obesity of 
bone 
[68]
.  
The number of diabetic population in India had already reached 60 
million it’s the right time to concentrate on the much underappreciated 
complications of diabetes like osteoporosis in addition to micro and 
macro vascular complications which have been addressed extensively. 
It’s not elusive what is contributing to decreased BMD in diabetes 
either the adiposity associated with T2DM is the major contributing 
factor via leptin pathway or diabetes per se is contributing to 
pathogenesis via it’s collagen cross linking pathway. With diabetes 
providing a substrate for obesity and obesity proving a substrate for 
osteoporosis, these three disorders are inter mingled and a holistic 
approach is needed to address these three complicated issues. 
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Hypothesis generation: 
With recent advances in modern science and the increase in life 
expectancy places osteoporosis as one of the major health public 
problems to be addressed in the India. There are studies which have 
showed conflicting results, with diabetes is protective against the 
development of osteoporosis 
[69]
. But subsequent studies had not proved 
so. If at all low BMD is a complication of diabetes, whether obesity is the 
major risk factor for the development of low BMD or it’s a complication 
of diabetes per se is to be ascertained. If there is any additional 
contributing factors like levels of vitamin D influencing the disease 
outcome will also be ascertained.  
With this study aimed at the assessment of BMD in obese and non- 
obese diabetics the pattern of prevailing bone mineral density in this 
subset of population (South East Asians) can be assessed. 
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MATERIALS AND METHODS 
This is a single center cross sectional study, done at Government 
Royapettah Hospital, Diabetology department. This study protocol was 
approved by the Ethical committee for research studies of Government 
Kilpauk Medical College Hospital, Chennai. 
INCLUSION CRITERIA: 
Patients admitted in the general ward of Government Royapettah 
Hospital for diabetic control and patients attending Diabetology 
department on outpatient basis are included in the study. Patients with 
T2DM were included in the study. Age group included in the study was 
less than 50 years. The study period is between July 2012- 
December2012.The patients recruited to this study were diagnosed to 
have diabetes using the American diabetes association criteria. Detailed 
clinical profile was noted, for each patient. Patients with written informed 
consent about the procedure were subjected to DEXA imaging for the 
evaluation of osteoporosis.  
EXCLUSION CRITERIA: 
1. Age more than 50 years. 
2. Smoker. 
 3. CKD. 
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 4. Patients on calcium and Vitamin D supplementations. 
5. Patients with drugs affecting calcium metabolism. 
6. Patients taking pioglitazone for diabetes. 
7. Female patients who had attained menopause were excluded from 
    the study. 
8. Patients with peripheral neuropathy and cataracts. 
9. Patients with proven underlying malignancy. 
Statistical analysis was done to identify significance and correlation 
between bone mineral density and obesity. Statistical analysis was done 
using SSPS 15 software. Univariate analysis was done with paired t test 
and Pearson product moment correlation coefficient.  
A Total of 50 patients, all of them fulfilled the ADA criteria for 
diabetes were subjected to DEXA imaging. All the patients included in 
the study were type 2 diabetes mellitus. Out of 50 patients included in the 
study 25 patients were obese, fulfilling the WHO criteria for obesity. 
Body mass index of more than 30 were included in the test group. 
Patients with normal body mass index, fulfilling WHO criteria with a 
BMI of less than 24.99 were included in the control group. The control 
group consists of 25 patients. The sex ratio being approximately equal in 
both test and control group. Hence forth sex as a confounding variable 
had been removed if it had been present. 
 
 
58 
 
OBSERVATIONS AND RESULTS 
TABLE-1:  
SEX COMPOSITION OF STUDY POPULATION. 
SEX OBESE NONOBESE 
MALE 13 12 
FEMALE 12 13 
 
TOTAL NUMBER OF OBESE DIABETICS= 25 
TOTAL NUMBER OF NON OBESE DIABETICS= 25 
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SEX COMPOSITION IN BOTH GROUPS 
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TABLE 2: 
SEX COMPOSITION AND COMPARISON WITH IN THE GROUP  
AND BETWEEN GROUPS. 
   SEX 
Total    Male Female 
Group Obese Count 13 12 25 
% within Group 52.0% 48.0% 100.0% 
Non_obese Count 12 13 25 
% within Group 48.0% 52.0% 100.0% 
Total Count 25 25 50 
% within Group 50.0% 50.0% 100.0% 
P=1.000[NS]- sex composition statistically not significant. 
Variables measured in the study: 
The important variables that were measured while subjecting the 
patient to DEXA imaging – lunar prodigy 2nd generation scanner that uses 
pencil beam for the evaluation of BMD are total fat percent of the body, 
type and distribution of fat content - that is android and gynoid obesity, 
lean mass and the important variable that negates the net weight bearing 
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effect on the bone, the percent fat mass. The T and Z scores of lumbar 
spines were taken as standard for the assessment of BMD.  
The percent fat mass is calculated from the two known variable 
from the data obtained from DEXA imaging. It is the ratio between the 
fat mass to body weight. 
                                                         FAT MASS [GRAMS] 
PERCENT FAT MASS =  
                TOTAL BODY WEIGHT [GRAMS] 
 
 
The above observation shows the average fat percentage in obese 
group was 48.1% and in non- obese group was 31.1% 
CHART 2 CHART-2; DISTRIBUTION OF FAT IN OBESE AND NON 
OBESE DIABETICS DIABETICS. 
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TABLE -3  
VARIABLES MEASURED 
Group Age Weight Height BMI Fat per Duration 
Obese Mean 41.336 85.824 159.36 33.577 48.076 10.840 
N 25 25 25 25 25 25 
Std. 
Deviation 
5.3582 14.2375 7.697 4.9652 4.4549 3.3126 
Minimum 28.5 60.0 140 24.6 39.0 3.0 
Maximum 50.0 125.9 172 52.4 57.0 16.0 
Non-
obese 
Mean 42.000 60.400 163.04 22.482 31.112 11.520 
N 25 25 25 25 25 25 
Std. 
Deviation 
4.3493 6.3836 6.387 1.3779 6.1758 3.2031 
Minimum 34.0 50.0 149 19.4 23.6 7.0 
Maximum 48.0 70.0 174 24.5 44.4 18.0 
Total Mean 41.668 73.112 161.20 28.029 39.594 11.180 
N 50 50 50 50 50 50 
Std. 
Deviation 
4.8415 16.8563 7.242 6.6638 10.0903 3.2431 
Minimum 28.5 50.0 140 19.4 23.6 3.0 
Maximum 50.0 125.9 174 52.4 57.0 18.0 
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In addition, the study and control population were subjected to 
vitamin D analysis using CLIA method. 
From the measured variables the mean BMI in obese diabetics was 
33.577 and in non-obese it was 22.482. The mean fat distribution in obese 
group was 48.076% where as that of non-obese group was 31.112%. The 
proportion of android and gynoid fat distribution is almost similar in 
obese diabetic group with android distribution being 51% and gynoid 
type was 48.2%. 
The mean Bone Mineral Density in obese diabetics was 1.0856 
g/cm2, where as that of non-obese group was 1.32232. The average 
vitamin D levels observed in this study in obese diabetics was 23.059 
ng/dl and in non-obese patients was 27.596 ng/dl. The mean Percent Fat 
Mass [PFM] in obese diabetics was 0.417 and in non-obese group it was 
0.2688. 
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TABLE-4 
VARIABLES MEASURED CONTINUED. 
Group VIT_D 
ANDROID 
FAT 
GYNOID 
FAT BMD PFM 
Obese Mean 23.059 51.000 48.219 1.08536 .41728 
N 25 25 25 25 25 
Std. Deviation 3.8362 6.2066 5.2614 .137835 .085892 
Minimum 19.6 39.7 38.3 .879 .256 
Maximum 34.6 65.4 59.2 1.324 .561 
Non-obese Mean 27.596 33.672 28.320 1.32232 .26880 
N 25 25 25 25 25 
Std. Deviation 6.2004 6.5839 6.0570 .131812 .041467 
Minimum 19.0 3.6 18.5 1.067 .198 
Maximum 46.0 39.4 38.6 1.497 .342 
Total Mean 25.328 42.336 38.270 1.20384 .34304 
N 50 50 50 50 50 
Std. Deviation 5.5937 10.8026 11.5127 .179274 .100398 
Minimum 19.0 3.6 18.5 .879 .198 
Maximum 46.0 65.4 59.2 1.497 .561 
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TABLE-5 
 
ABNORMAL BMD IN OBESE AND NONOBESE  
DIABETICS COMPARED 
 
TYPE OSTEOPENIA OSTEOPOROSIS TOTAL 
OBESE 
DIABETIC 
16 4 25 
NON OBESE 
DIABETIC 
3 - 25 
 
Total number of patients with osteopenia in both groups were 19 
[total number=50] and total number of patients with osteoporosis were 
4[total number = 50] 
In total 38% of the diabetics had osteopenia whereas only 8% of  
the total diabetic population including both obese diabetic and non-obese 
diabetics exhibited osteoporosis.  
So from the above observation it is clear that osteopenia may be 
the most prevailing type of abnormal BMD in obese diabetic population.  
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TABLE-6 
COMPARITIVE PREVALENCE OF OSTEOPENIA IN OBESE  
AND NON OBESE DIABETICS 
 
   OSTEOPENIA 
Total    Yes No 
Group Obese Count 16 9 25 
% within Group 64.0% 36.0% 100.0% 
Non-obese Count 3 22 25 
% within Group 12.0% 88.0% 100.0% 
Total Count 19 31 50 
% within Group 38.0% 62.0% 100.0% 
P=0.000 
The prevalence of osteopenia in obese diabetics were 64% P < 
0.05[significant] 
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TABLE-7 
COMPARITIVE PREVALENCE OF OSTEOPOROSIS  
IN OBESE AND NON OBESE DIABETICS 
 
   OSTEOPOROSIS 
Total    Yes No 
Group Obese Count 4 21 25 
% within Group 16.0% 84.0% 100.0% 
Non-obese Count 0 25 25 
% within Group .0% 100.0% 100.0% 
Total Count 4 46 50 
% within Group 8.0% 92.0% 100.0% 
P=0.110 
The prevalence of osteoporosis alone in obese diabetics was 16%. 
P = 0.110 [not significant] 
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As noted from the above observation out of 25 patients in obese 
diabetic group 20 of them had abnormal bone mineral density. Out of 20 
patients 16 of them were osteopenic and only 4 of the patients were 
osteoporotic. This observations is statistically significant [P = < 
0.000].whereas in the control group that consists of non-obese diabetics 
the total number of patients with abnormal BMD is only three. All three 
of them were osteopenic and none exhibited the pattern of osteoporosis. 
The above observation was not statistically significant [P=0.110]. 
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TABLE-8 
T-TESTSHOWING NO STATISTICAL CORRELATION IN DURATION 
 Group N Mean Std. Deviation P-value 
AGE Obese 25 41.336 5.3582 
0.633 
Non-obese 25 42.000 4.3493 
DURATION Obese 25 10.840 3.3126 
0.464 
Non-obese 25 11.520 3.2031 
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From the above observations the age clustering was early 40’s in 
both the sex for both obese and non-obese diabetics. When tests of 
significance were performed for both age and duration influencing the 
outcome of the study, there was no statistical significance of either. 
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CHART-5 MEAN DURATION OF DIABETES IN THE STUDY AND 
CONTROLS 
 
 
70 
 
TABLE-9 
SHOWING STATISTICAL CORRELATION BETWEEN T AND Z SCORE 
WITH REFERENCE TO BMD 
 Group N Mean Std. Deviation P-value 
T SCORE Obese 25 -1.360 1.2066 
0.000 
Non-obese 25 1.648 1.4057 
Z SCORE Obese 25 -1.200 1.0642 
0.000 
Non-obese 25 1.124 1.2166 
BMD  Obese 25 1.08536 .137835 
0.000  
Non-obese 
25 1.32232 .131812 
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The above observation shows the comparison between T and Z 
scores and the bone mineral density in obese and non -obese diabetics. 
The average T score in obese diabetic was – 1.360 which is in the 
osteopenic range [A score of -1 to -2.5 indicates osteopenia]. The average 
Z score being -1.20 in obese diabetic.  
For both the variables compared with BMD the P value was 
statistically significant [P = 0.000]. 
        The average BMD in obese diabetics were 1.08536 when compared 
to non -obese  diabetics  were  1.32232  which is statistically significant 
[P = 0.000]. 
 
CHART-6 COMPARISON BETWEEN BMD OF OBESE AND NON OBESE DDIABETIC  
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TABLE-10 
T TEST AND GROUP STATISTICS BETWEEN VARIABLES  
MEASURED BY DEXA 
 Group N Mean Std. Deviation P-value 
BMI Obese 25 33.577 4.9652 
0.000 
Non-obese 25 22.482 1.3779 
FAT PER Obese 25 48.076 4.4549 
0.000 
Non-obese 25 31.112 6.1758 
VIT_D Obese 25 23.059 3.8362 
0.003 
Non-obese 25 27.596 6.2004 
ANDROID FAT Obese 25 51.000 6.2066 
0.000 
Non-obese 25 33.672 6.5839 
GYNNOID FAT Obese 25 48.219 5.2614 
0.000 
Non-obese 25 28.320 6.0570 
BMD  Obese 25 1.08536 .137835 
0.000 
Non-obese 25 1.32232 .131812 
PFM Obese 25 .41728 .085892 
0.000 
Non-obese 25 .26880 .041467 
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The average percent fat mass [PFM IN X AXIS] in obese diabetics 
were 0.417 and in non- obese group were 0.28 
 
The average vitamin D levels[X -AXIS] in obese group were 23.1 
ngml and in non obese were 27.6 ng/ml 
CHART-7;COMPARISON OF PERCENT FAT MASS IN BOTH 
GROUPS 
CHART-8: COMPARISON OF VITAMIN D LEVELS IN BOTH GROUPS 
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The mean value of vitamin D levels falls between the range of 20 
to 25 ng/ml in obese diabetics. 
 
The mean value of vitamin D levels falls between the range of 25 
to 35 ng/ml in non-obese diabetics. 
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The above observation regarding the comparison of vitamin D 
levels with reference to BMI in obese and non -obese diabetics indicates 
both the groups were vitamin D insufficient. The average vitamin D 
levels in obese diabetics were23.059 ng/ml,where as that of non-obese 
diabetics was slightly on the higher side with a mean value of 27.59 
ng/ml. But as per the international levels both groups were vitamin D 
insufficient if not deficient. The P value in group statistics is significant 
[P = 0.003], but within the obese diabetics the correlation between BMI 
and vitamin D levels were not statistically significant. 
 
The above observation shows the distribution of android and 
gynoid fat in obese and non -obese diabetics. There is a statistical 
correlation between pattern of obesity and the mean BMD. The mean 
android fat mass was 51.0 % and mean gynoid mass was 48.219% in 
obese diabetics and BMD of obese people was 1.085 g/cm
2 
. Meanwhile 
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CHART-11: DISTRIBUTION OF ANDROID AND GYNOID FAT IN OBESE AND 
NON OBESE DIABETICS WITH REFERENCE TO BMD 
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the mean android fat mass in non-obese diabetic was 33.672% and gynoid 
fat mass was 28.32% and BMD of non-obese patients was 1.32232. The 
correlation between the type of fat mass and BMD was statistically 
significant with both android and gynoid obesity associated with 
decreased BMD[P = 0.000]. 
TABLE-11 
COMPARISON OF BMD WITH PFM SHOWS STATISTICAL 
SIGNIFICANCE 
Group N Mean STANDARD 
DEVIATION 
P Value 
BMD            OBESE 
 
             NON  OBESE 
25  
 
25 
1.085 
 
1.32232 
 
 
 
0.000 
PFMOBESE 
 
NON  OBESE 
 
 
25  
 
25 
0.41728 
 
0.26880 
.041467 
 
0.000 
0.138735 
   0.131812 
.085892 
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From the above observation it is obvious that when the percent fat 
mass is more, there is a decrease in BMD. The mean fat mass in obese 
diabetic is 0.417 and the mean BMD in obese diabetic was 1.085 g/cm2. 
Whereas the mean fat mass for a non- obese diabetic was 0.26880 and 
mean BMD for non- obese diabetic was 1.32232. The observation was 
statistically very significant [P = 0.000]. 
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Chart-12: COMPARISON OF PFM AND BMD IN OBESE 
AND NON OBESE DIABETICS 
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TABLE-12 
PEARSONS CORRELATION BETWEEN VARIABLES 
  
BMI T SCORE Z SCORE VIT_D DURATION 
BMI Pearson 
Correlation 
1 -.701
**
 -.714
**
 -.426
**
 .063 
Sig. (2-tailed)  .000 .000 .002 .665 
N 50 50 50 50 50 
T SCORE Pearson 
Correlation 
-.701
**
 1 .977
**
 .529
**
 -.096 
Sig. (2-tailed) .000  .000 .000 .505 
N 50 50 50 50 50 
Z SCORE Pearson 
Correlation 
-.714
**
 .977
**
 1 .546
**
 -.108 
Sig. (2-tailed) .000 .000  .000 .456 
N 50 50 50 50 50 
VIT_D Pearson 
Correlation 
-.426
**
 .529
**
 .546
**
 1 -.200 
Sig. (2-tailed) .002 .000 .000  .164 
N 
50 50 50 50 50 
DURATI
ON 
Pearson 
Correlation 
.063 -.096 -.108 -.200 1 
Sig. (2-tailed) .665 .505 .456 .164  
N 50 50 50 50 50 
**. Correlation is significant at the 0.01 level (2-tailed).   
From the above observation with reference to Pearson correlation 
which signifies an inverse correlation between the body mass index and 
the T score, Z score, vitamin D levels. All the correlation between these 
variables is statistically significant with a P value of < 0.05. With 
reference to Pearson sign which indicates the direction of relation 
between the variables in which T and Z scores are positively correlated 
and infact T score acts as a surrogate marker of  Z score and viceversa. 
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The clustering of T score value between -1.0 to -3 in patients with 
a BMI of > 30 
 
The clustering of Z score between -1.0 and -2.5 in patients with 
BMI of > 30 
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The clustering of T score between 0.4 -0.5 with reference to PFM 
in obese diabetics. 
 
The clustering of Z score as of T score between0.4 - 0.5with 
reference to PFM in obese diabetics. 
0 0.1 0.2 0.3 0.4 0.5 0.6
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
T SCORE 
 
CHART-15: COMPARISION BETWEEN T SCORE AND 
PERCENT FAT MASS OF OBESE DIABETIC 
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TABLE-13 
ANOVA 
  Sum of Squares df Mean Square F Sig. 
VIT_D Between 
Groups 
575.236 2 287.618 14.111 .000 
Within 
Groups 
957.953 47 20.382 
  
Total 1533.189 49    
BMD  Between 
Groups 
.939 2 .469 34.680 .000 
Within 
Groups 
.636 47 .014 
  
Total 1.575 49    
 
In the analysis of variance in which comparison was made between 
more than 2 groups the mean vitamin D levels across the groups is 
statistically significant and significantly different among groups. 
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TABLE-14 
 
 
ANOVA 
 
  Sum of 
Squares df 
Mean 
Square F Sig. 
VIT_D Between 
Groups 
364.312 2 182.156 7.324 .002 
Within Groups 1168.877 47 24.870   
Total 1533.189 49    
BMD  Between 
Groups 
.651 2 .326 16.566 .000 
Within Groups .924 47 .020   
Total 
1.575 49 
   
 
 
 
 
  
   
 
Though Z score is not as significant as T score as PFM increases 
there is increase in negativity of Z score [P<0.05] 
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The clustering of positivity inT score of non -obese diabetics due to 
decreased percent fat mass. 
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DISCUSSION 
In our study the prevalence of abnormal bone mineral density 
among obese diabetics was 80%[cumulative]. Out of which more than 
75% with abnormal BMD had osteopenia rather than osteoporosis. 
Overall the prevalence rate of abnormal BMD in diabetic population with 
reference to T score is 46% and with reference to Z score is 38%. There 
was no statistical sex difference in the prevalence of abnormal BMD, as 
the confounding factors like menopause and other causes of secondary 
osteoporosis like alcoholism; smoking and systemic disease had been 
removed. 
In accordance with cross sectional studies by Zhao et al and Hsu et 
al in Chinese population the important observation was that, there was an        
inverse correlation between the percent fat mass and BMD. In their study 
they had found out that more the percent fat mass lesser will be the BMD. 
The difference between their study model and ours was the number of 
subjects included and they inducted genetic and environmental factors in 
their study. Ours was an observational study involving a specific subset 
of a population involving diabetics. The important observation from our 
study is the relationship between fat mass and obesity is not arbitrary in 
fact the observation of decreased BMD in obese diabetics when compared 
to non-obese diabetics who has comparatively normal BMD reiterates the 
new theory that fat mass is no more protective in fact it is deleterious to 
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bone health. The average mean Percent fat mass in obese group were 
0.417 as compared to 0.268 which is in very much accordance with study 
by Zhao et al in which they observed PFM is more in obese subjects. 
The above observation supports the fact indirectly that larger 
muscle mass imparts a greater mechanical loading on the skeleton, when 
this loading effect is removed the net effect of total body fat mass 
excluding the muscle mass [i.e., lean mass] is detrimental to bone health. 
In our study by excluding the impact of muscle loading on the skeleton 
by accounting the percent fat mass which is the ratio of fat mass in grams 
to total body weight in grams shows an inverse association between BMD 
and obesity. Hence this observation challenges the concept that obesity is 
protective against the development of osteoporosis. 
Our study did not find any sex difference in the prevalence of 
abnormal BMD, since the main confounding variable in the female 
population of our study was menopause which was excluded before 
inducting the patients in to the study by pre study questionnaire. 
In addition we didn’t find any correlation between the duration of 
diabetes and the occurrence of osteopenia or osteoporosis. This finding is 
in accordance with previous studies from Barret et al [79] who had 
showed no correlation between the duration of diabetes and abnormality 
in BMD. We didn’t include the glycemic status of the patient in the study 
as previous studies from Valerio et al [80] and others had clearly showed 
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no correlation between the glycemic status and abnormal BMD though 
the pathogenic mechanism behind abnormal BMD in diabetics possibly 
due to abnormal glycation of type 1 collagen and other proteins may be 
involved. All of the above mentioned studies had compared the HbA1C 
levels with lumbar BMD, which they found no correlation. The incidence 
of fracture rate in study group was only 12%,only two of the patients in 
the obese group had fracture. One had fracture coccyx and the other 
patient had fracture of forearm following trauma which was not trivial. 
The confounding variable for the increased frequency of falls like 
presence of cataract and peripheral neuropathy was excluded from the 
study group.  
Regarding the influence of diabetes mellitus on bone mineral 
density various studies had shown contrasting results. A study by petit et 
al had showed a positive correlation between the BMD and T2DM, in his 
study he had shown higher BMD in elderly diabetics when compared to 
age matched non diabetics[81]. This in contrast to study by Yaturu et al in 
which he had showed a negative correlation between BMD and T2DM in 
which he had observed lesser BMD in patients with T2DM for age 
matched normal subjects[82]. In our study we didn’t find any correlation 
between diabetes perse and BMD,because the impact of obesity on BMD 
had strongly correlated in our study. However the concept that obesity 
associated with T2DM is protective against the development of 
osteoporosis is strongly challenged by the fact that in our study group 
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compromising of obese diabetics out of 25 patients subjected to DEXA 
imaging 16 of them had osteopenia (64%) and 4 of them had osteoporosis 
(16%), whereas out of 25 patients in non- diabetic group subjected to 
DEXA only 3 (6%) of them had osteopenia. These findings are very 
much in favor of the current prevailing concept that excess fat mass is 
detrimental to bone homeostasis which is supported by the observation  
discussed in detail previously that excess adiposity leads to more 
expression of  leptin hormone , which in turn via its central sympathetic 
effects leads to decrease in bone mineral density. 
         With reference to vitamin D levels and the body mass index the 
findings in our study had showed a mean vitamin D levels of 28.427 
ng/ml, in patients with adequate bone mineral density. Where as in 
patients with osteopenia both in obese and non- obese group the mean 
vitamin D levels were 21.418 ng/ml. This observation was statistically 
significant [P < 0.05]. In patients with osteoporosis the mean vitamin D 
levels were 23.5 ng/ml .The fact that even though these patients are 
osteoporotic they had slightly higher vitamin D levels when compared to 
osteopenic group is probably related to the insufficient number in the 
osteoporotic group[ N=4] . However the important observation in this 
study is that the mean vitamin D levels in obese population is 23.059 
ng/ml, when compared to non- obese group who had a mean vitamin D 
levels of 27.596 ng/ml is statistically significant[ P<0.05]. The fact that 
both these groups are vitamin D insufficient is in accordance with 
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previous studies in vitamin D in patients with diabetes
[84,85]
. The 
increased prevalence of abnormal BMD observed in obese diabetic 
population is due to increased PFM that has a negative impact on bone 
rather than due to insufficient levels of vitamin D because both groups 
had insufficient vitamin D levels but the levels were less in obese 
diabetics. 
 The most common pattern of bone mineral density in obese 
diabetic in this study was osteopenia with a prevalence of 64%. However 
the prevalence of osteoporosis in obese diabetics was only 16%. Because 
osteopenia and osteoporosis are continuing spectrum of same disease it is 
imperative to consider osteopenia is as detrimental as other micro 
vascular and macro vascular complications of diabetes. There has been no 
study correlating the pattern of bone mineral density of obese diabetic 
and non- obese diabetics which, if present will help us to know about the 
pathophysiology in detail apart from leptin pathway, any other 
mechanism is involved in the pathogenesis. 
Limitations of the study: 
 The sample size was small and further studies with larger number 
 of people have to be done to verify the results. 
 Since the study was done in ethnic Asian population further studies 
 are needed in large population involving same and different ethnic 
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 group to verify the reproducibility of the results. As most of the 
 reference studies are from Caucasians and Sino Asians. 
 Environmental influence on bone health has not been taken in to 
 consideration, as factors like nutrition may affect the bone health 
 adversely. 
 Glycemic status has not been taken in to consideration, which may 
 be a possible determinant factor in outcome, though most western 
 studies had not included glycemic status in assessing BMD. 
Implications for the future: 
 Obesity and diabetes can be included in the screening process for 
 osteoporosis. 
 Guidelines for DEXA imaging can be expanded to include 
 diabetics. 
 Screening for vitamin D levels is mandatory for all diabetics, as per 
 the WHO guidelines all most all patients in our study were vitamin 
 D insufficient. 
 Supplementation of vitamin D may be needed for those patients 
 who are insufficient, even though they are asymptomatic. 
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 Strict aerobic and weight bearing exercises are advocated for obese 
 diabetics to prevent the detrimental effect of obesity on bone. 
 Studies currently available had shown contrasting results between 
 fat and bone this is because of complicated nature of relationship 
 between bone and fat. More studies using molecular and genetic 
 methodology is needed to design an interventional protocol for 
 obesity and osteopenia together. 
 Since most of the available studies with reference to obesity and 
 abnormal BMD are cross sectional in nature which has an inherent 
 fallacy in dissecting out the truth, further studies of longitudinal in 
 nature and strong design are essential to find out the true relevance 
 of fat mass on bone homeostasis. 
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CONCLUSIONS 
In our study, 
 Obesity is one of the important risk factor for the development of 
 osteopenia inType 2 diabetes mellitus. 
 It was observed that percent fat mass was an important factor in 
 predicting abnormal BMD rather than total body weight in obese 
 individual. 
 Both android and gynoid fat distribution in excess had negatively 
 correlated with abnormal BMD. 
 Vitamin D levels were significantly lowered in obese diabetics 
 when compared to non -obese diabetics though both the group had 
 showed insufficient levels of vitamin D. 
Disclosure 
          The investigator had not received any form of support or grant 
 from any institution or pharmaceutical company. 
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cas
e 
No NAME 
AG
E SEX 
WEIGH
T 
HEIGH
T BMI 
T 
SCOR
E 
Z 
SCOR
E FAT % 
OSTEOPENI
A 
OSTPOROSI
S 
MENOPAUS
E 
DURATIO
N 
ETHNI
C 
OP/IP 
NO 
VIT-
D 
level
s 
H/O 
fracture
s 
ANDROI
D FAT 
GYNNOI
D FAT 
BMD 
g/cm
2 PFM 
1 MRS.ROOKIAH 45 
FEMAL
E 125.9 155 52.4 -1.5 -2.6 53% YES NO NO 12 ASIAN 6872 21.3 YES 49.1 59.2 1.000 
0.51
9 
2 MISS RANI 38 
FEMAL
E 89 168 
31.5
3 -1.6 -1.7 51% YES NO NO 8 ASIAN 7765 
20.5
7 NO 46 42 1.061 
0.47
6 
3 MRS.RAJI 40 
FEMAL
E 75 152 32.5 -2.7 -2.1 50% NO YES NO 11 ASIAN 3426 19.6 NO 54.3 53.9 1.198 
0.47
3 
4 
MRS 
ERAVAMMAL 46 
FEMAL
E 97 169 
33.9
6 -1.6 -1.5 48% YES NO NO 11 ASIAN 
10065
7 21 NO 48 44 1.296 
0.40
1 
5 MR.ABRAHAM 35 MALE 82 160 
32.0
3 -2.2 -2 46% YES NO NA 7 ASIAN 4562 23.4 NO 46.8 45.6 1.257 
0.39
8 
6 MR.MUBARAK 40 MALE 75 156 
30.8
1 -1.9 -1.5 
41.60
% YES NO NA 3 ASIAN 6456 19.8 YES 49.7 46.7 1.309 
0.38
6 
7 MR.NAHOOR 36 MALE 89.7 161 34.6 -1.3 -1.7 42% YES NO NA 7 ASIAN 1034 
20.8
1 NO 49.7 46.7 1.062 
0.40
2 
8 MRS.ANDAL 29 
FEMAL
E 78 154 32.8 -0.9 -1.3 39% NO NO NO 7 ASIAN 2341 34.6 NO 43.3 44.7 1.012 
0.40
1 
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9 MRS.JOTHI 41 
FEMAL
E 68 148 
31.0
4 -1.2 -1.1 41% YES NO NO 13 ASIAN 1789 21 NO 39.7 50.08 1.031 
0.43
8 
10 MR.ASLAM 44 MALE 87 163 
32.7
4 -1.8 -1.6 47% YES NO NO 8 ASIAN 1490 22.3 NO 47.6 41.7 1.004 
0.44
1 
11 AMBALAVANAR 46 MALE 84 164 
31.2
3 -1.7 -1.6 43% YES NO NO 16 ASIAN 4562 21.4 NO 51.4 41.8 1.012 
0.50
3 
12 VENKATESH 37 MALE 78 154 
32.8
8 -2 -1.6 46% YES NO NO 13 ASIAN 6574 20.4 NO 54.3 45.8 0.999 
0.45
2 
13 
KOTHANDARAMA
N 50 MALE 88 165 
32.3
2 -2.4 -1.5 51 YES NO NO 16 ASIAN 8934 21.6 NO 63.6 50.9 0.937 
0.50
1 
14 PRABHU 34 
FEMAL
E 76 157 
30.8
3 -1.6 -1.8 47% YES NO NO 9 ASIAN 6731 24 NO 50.6 53.6 1.007 
0.39
9 
15 VAIRAMUTHU 47 MALE 94 164 
34.9
4 -2.8 -2.1 55% NO YES NO 14 ASIAN 7811 26.7 NO 61.2 54.6 0.879 
0.56
1 
16 RANGACHARI 46 MALE 112 162 
42.6
7 -2.5 -1.9 53% NO YES NO 16 ASIAN 
11103
2 22.4 NO 65.4 56.2 0.923 
0.49
8 
17 YASIN  47 
FEMAL
E 91 168 
32.2
4 -2.4 -1.6 50% YES NO NO 11 ASIAN 6509 21.4 NO 54.4 53.2 1.002 
0.39
5 
18 RANGAN 46 MALE 89 156 
36.5
7 0.8 0.7 48% NO NO NO 13 ASIAN 9084 25.7 NO 48.4 43.7 1.272 
0.31
1 
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19 VELAMMAL 39 
FEMAL
E 70 140 
31.5
3 1.2 1.1 49% NO NO NO 10 ASIAN 5621 33.2 NO 49 38.3 1.198 
0.30
1 
20 JOTHI 42 
FEMAL
E 72 148 
32.8
7 -1.2 -1.1 49% YES NO NO 12 ASIAN 2314 21 NO 49.3 50.8 1.031 
0.47
8 
21 ROSALYN 44 
FEMAL
E 76 154 
32.0
4 -1.4 -1.2 53% YES NO NO 15 ASIAN 6723 
20.6
3 NO 56.7 47.3 1.003 
0.39
7 
22 DURMA 39 male 82 158 
32.8
4 -1.2 -1.1 48% YES NO NO 10 ASIAN 7612 
20.4
7 NO 53 47.2 1.112 0.41 
23 RANI 42 
FEMAL
E 87 167 
31.1
9 0.8 1 47.3 NO NO NO 9 ASIAN 7323 22 NO 46 48.5 1.295 
0.25
6 
24 KUMARAN 37 MALE 96 172 
32.4
4 1.4 -0.6 47% NO NO NO 8 ASIAN 8943 27 NO 45 49 1.324 
0.26
5 
25 HARIKRISHNAN 50 male 102 167 
36.5
7 -2.6 -2.1 57% NO YES NO 12 ASIAN 4319 24.2 NO 56.3 53.2 0.964 
0.40
2 
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case 
no name  age  sex weight height BMI 
T 
score 
Z 
score 
fat 
% osteopenia osteoporosis MENOPUASSE duration ethnicity 
op/ip 
NO 
VIT D 
ng/ml 
H/O 
FRACTU 
Android 
obese 
GYNEOID 
OBE 
BMD 
g/cm2 PFM 
1 RAMASWAMY 43 male 56 164 20.82 1.8 1.3 33.7 NO NO NA 12 ASIAN 5543 22.4 NO 38.5 22.7 1.237 0.236 
2 AYYAPAN 46 male 58 167 20.79 2.4 1.8 27.3 NO NO NA 8 ASIAN 1784 26.7 NO 33.4 26.7 1.342 0.289 
3 MOHAMAD GALINI 47 male 52 154 21.92 2.1 1.4 32.9 NO NO NA 11 ASIAN 2907 34.9 NO 35.2 21.7 1.412 0.257 
4 GOVARDANAN 39 male 70 170 24.22 2.6 1.8 33 NO NO NA 14 ASIAN 2253 37.3 NO 36.7 22.4 1.497 0.301 
5 HARIBASKAR 41 male 57 166 20.68 2.2 1.5 29 NO NO NA 10 ASIAN 7865 46 NO 38 27 1.489 0.321 
6 VENU 40 male 58 161 22.32 2.3 1.8 28.6 NO NO NA 13 ASIAN 6745 26.7 NO 33.6 20.6 1.356 0.198 
7 NARANGI 36 male 70 174 23.12 2.3 1.6 34.2 NO NO NA 7 ASIAN 4589 28.3 NO 32.1 22.7 1.345 0.235 
8 SOLAYAPPAN 45 male 57 163 21.45 2.6 1.5 23.7 NO NO NA 9 ASIAN 5639 23.2 NO 32.6 22.6 1.321 0.276 
9 SOUNDARAPANDIAN 47 male 67 168 23.73 -1.7 -1.6 43.2 YES NO NA 13 ASIAN 6783 20.17 NO 36.8 32.6 1.067 0.31 
10 JOSEPH MOSES 48 male 66 169 23.1 2.2 1.5 32.3 NO NO NA 17 ASIAN 8943 18.98 NO 3.6 32.1 1.387 0.289 
11 LINGAPPAN 38 male 50 156 20.54 1.9 1.7 32.7 NO NO NA 8 ASIAN 2145 21.56 NO 32.5 18.5 1.476 0.293 
12 PERUMAL SWAMY 39 male 59 165 21.67 2.6 2.1 24.7 NO NO NA 7 ASIAN 3786 28.9 NO 35.7 21.6 1.421 0.299 
13 Lakshmi  37 female 50 156 20.54 0.3 0.8 36.7 NO NO NO 11 ASIAN 7893 31.2 NO 42 42.7 1.215 0.34 
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14 KOTHAI 34 female 61 163 22.95 2.6 2.1 30.5 NO NO NO 7 ASIAN 6749 34.1 NO 32.5 23.4 1.342 0.219 
15 GEETHA 48 female 51 149 22.97 2.8 2.1 26.9 NO NO NO 11 ASIAN 5634 24.6 NO 35.7 32.5 1.442 0.223 
16 SEVAMBAL 47 female 62 161 22.77 2.1 1.3 23.6 NO NO NO 12 ASIAN 8902 27.8 NO 33.5 36.6 1.267 0.271 
17 ARIVUKANNU 43 female 70 169 24.5 2.3 1.6 26.7 NO NO NO 13 ASIAN 7865 22.3 YES 34.6 26 1.443 0.321 
18 SENTHAMARAI 44 female 54 167 19.36 2.5 2.3 24.2 NO NO NO 15 ASIAN 6743 28.6 NO 35.5 26 1.397 0.302 
19 ANNAMMAL 41 female 57 163 21.45 -0.7 -0.9 42 NO NO NO 13 ASIAN 2214 26.7 NO 36.7 34.6 1.118 0.237 
20 CHIMTAMANI 39 female 68 168 24.09 -1.2 -1.5 44.4 YES NO NO 15 ASIAN 2300 23.1 NO 33.5 38.6 1.098 0.342 
21 FOUZEA MOL 38 female 57 158 22.83 2.5 2.1 27.8 NO NO NO 11 ASIAN 4532 33.5 NO 32.3 30.6 1.41 0.217 
22 AFSANA 39 female 68 163 21.82 2.7 1.5 26.4 NO NO NO 9 ASIAN 2089 29.6 NO 34.5 32.7 1.387 0.222 
23 SARAVANI 37 female 61 159 24.12 0.8 0.6 32.5 NO NO NO 8 ASIAN 4078 29.4 NO 35.8 36.7 1.143 0.234 
24 MYTHILI 46 female 58 155 24.14 -1.2 -1.8 40.7 YES NO NO 16 ASIAN 7563 21.6 NO 33.3 37.8 1.087 0.307 
25 NELLAIAMMAL 48 female 69 172 23.32 2.6 1.5 33 NO NO NO 18 ASIAN 8902 22.3 YES 39.4 32.4 1.345 0.218 
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LIST OF ABBREVIATIONS USED 
PFM Percent Fat Mass. 
 
FFM Fat Free Mass. 
 
T2DM 
 
Type 2 Diabetes Mellitus. 
T1DM Type 1 Diabetes Mellitus 
BMI Body mass index. 
 
RANKL    Receptor Activator of  
Nuclear Factor κβ 
 
NF κβ 
 
Nuclear Factor κβ. 
 
OPG Osteoprotegerin. 
 
DEXA       Dual Energy X ray 
Absorptiometry. 
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VDR     Vitamin D receptor. 
 
M-CSF    Macrophage Colony 
Stimulating Factor.  
 
 
ERα                                                                       Estrogen receptor α. 
TNF-α                                                                  
 
Tumor Necrosis Factor – α 
LRP5         LDL Receptor related protein 
5. 
BMP2                                                               
. 
 
Bone Morphogenic Protein 
 
COX2                                                                     cyclooxygenase 2.
 
NO          Nitric Oxide. 
 
AGEs       Advanced Glycation End 
products. 
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BMD Bone Mineral Density. 
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QUESTIONNAIRE 
 NAME / AGE / SEX / OCCUPATION / ADDRESS/IP/OP  NUMBER. 
 
 HISTORY:  
 Onset of diabetes. 
 Duration of DM. 
 Low back ache. 
 H/O Steroid intake. 
 Antiepileptic Medications. 
 H/O Small and large joint pain. 
 H/O Chronic cough. 
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 H/O Tremors. 
 H/O Chronic diarrohea. 
 H/O Bilateral feet swelling. 
 H/O Decreased urine output. 
 H/O Jaundice. 
 H/O Numbness of feet, stock and glove pattern of sensory loss. 
 H/O visual abnormalities. 
         H/O Loss of weight and appetite. 
 PAST HISTORY: 
 Systemic Hypertension, Dyslipidemia, CAD, CVA, PVD, COPD  
 
 
129 
 
 and Thyroidal illness, H/O Fractures and site. Past malignancy. 
 PERSONAL HISTORY:  
  Alcohol- Duration , Amount, Frequency. smoking,-Beedi,  /cigarette/Number /Day/ Duration. 
 MENATURAL HISTORY: Menopause, any other menstrual   
 abnormalities 
 DRUG HISTORY:  
           Calcium, vitamin D supplementation, Oral hypoglycemic agents      [pioglitazone] 
Antihypertensives,Antianginals, Other drugs  affecting calcium metabolism. 
GENERAL EXAMINATION 
VITALS- Blood pressure, Pulse rate. 
BMI [Height and Weight] 
SYSTEM EXAMINATION: CVS/RS/ABDOMEN/CNS  
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LOCAL EXAMINATION:  Foot ulcers, any joint abnormalities. 
• BLOOD SUGAR-FBS/PPBS 
• RFT 
• LFT 
• LIPID PROFILE 
• SERUM CALCIUM 
• 25(OH)VITAMIN D LEVELS 
• CHEST XRAY 
• CBC WITH ESR 
• DEXA 
     AGE 
     ETHNICITY 
     BMI 
   TOTAL FAT PERCENTAGE 
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     TOTAL FAT IN GRAMS 
     TOTAL BODY MASS IN GRAMS 
   PERCENT FAT MASS 
     DIATRIBUTION OF FAT [ ANDROID/GYNOID] 
   T- SCORE- LUMBAR SPINE 
Z – SCORE LUMBAR SPINE 
    BONE MINERAL DENSITY  
COMMENTS : 
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